Видео ютуба по тегу Doseescalation

Phase 1 Dose Escalation: Introduction to Adaptive Trial Designs using FACTS
Phase 1 Dose Escalation: Introduction to Adaptive Trial Designs using FACTS
Sayeh Lavasani, MD, MS | Neratinib and Dose Escalation | Optimizing Therapy for HER2+ Disease
Sayeh Lavasani, MD, MS | Neratinib and Dose Escalation | Optimizing Therapy for HER2+ Disease
FACTS: Comparing and Contrasting Dose Escalation Design Methods
FACTS: Comparing and Contrasting Dose Escalation Design Methods
Phase I dose-escalation and expansion study evaluating BI 907828 in patients with solid tumours
Phase I dose-escalation and expansion study evaluating BI 907828 in patients with solid tumours
Phase I dose-escalation study of fractionated dose 225Ac J591 for mCRPC
Phase I dose-escalation study of fractionated dose 225Ac J591 for mCRPC
Clinical Trials: A Principal Investigator Explains Dose Escalation, Phase by Phase.
Clinical Trials: A Principal Investigator Explains Dose Escalation, Phase by Phase.
Sramila Aithal, MD | Neratinib and Dose Escalation | Optimizing Therapy for HER2+ Disease
Sramila Aithal, MD | Neratinib and Dose Escalation | Optimizing Therapy for HER2+ Disease
Yifan Tu, MD | Neratinib and Dose Escalation | Optimizing Therapy for HER2+ Disease
Yifan Tu, MD | Neratinib and Dose Escalation | Optimizing Therapy for HER2+ Disease
Design of Adaptive Phase 1 Clinical Trials for Dose Escalation using the DEDUCE Application
Design of Adaptive Phase 1 Clinical Trials for Dose Escalation using the DEDUCE Application
A Competitive Alternative to Model-based Dose Escalation Procedures
A Competitive Alternative to Model-based Dose Escalation Procedures
Best Practices for Optimizing Dose Escalation in First in Human Studies
Best Practices for Optimizing Dose Escalation in First in Human Studies
Designs of dose escalation studies in phase I oncology trials
Designs of dose escalation studies in phase I oncology trials
Francis Arena, MD  | Neratinib and Dose Escalation | Optimizing Therapy for HER2+ Disease
Francis Arena, MD  | Neratinib and Dose Escalation | Optimizing Therapy for HER2+ Disease
Phase I Dose-escalation Study of Trametinib and Cisplatin in Patients with Advanced Soild Tumors
Phase I Dose-escalation Study of Trametinib and Cisplatin in Patients with Advanced Soild Tumors
Rationale, Dose Escalation for 67Cu-SAR-bisPSMA in Patients With mCRPC
Rationale, Dose Escalation for 67Cu-SAR-bisPSMA in Patients With mCRPC
ARTFORCE: Rationale and study design of radiotherapy dose escalation and toxicity risks for HNC
ARTFORCE: Rationale and study design of radiotherapy dose escalation and toxicity risks for HNC
Modern Dose Escalation Phase 1 Trials with East® ESCALATE
Modern Dose Escalation Phase 1 Trials with East® ESCALATE
Dose escalation designs with open enrollment
Dose escalation designs with open enrollment
FACTS Dose Escalation N-CRM Example
FACTS Dose Escalation N-CRM Example
Dose-escalation and expansion study of ivosidenib in patients with IDH1-mutant MDS
Dose-escalation and expansion study of ivosidenib in patients with IDH1-mutant MDS
Proactive Cohort Management for Mastering Dose Escalation in Early-Phase Development
Proactive Cohort Management for Mastering Dose Escalation in Early-Phase Development
Dose Escalation & Managing Toxicities of Neratinib
Dose Escalation & Managing Toxicities of Neratinib
Optimizing Chemotherapy Dosing: From Phase 1 Dose Escalation to Modification.
Optimizing Chemotherapy Dosing: From Phase 1 Dose Escalation to Modification.
Venetoclax dose-escalation and obinutuzumab treatment schedule in a clinical trial
Venetoclax dose-escalation and obinutuzumab treatment schedule in a clinical trial